A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

NCT03711188 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Melanoma

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: IMM-101

Sponsor

Immodulon Therapeutics Ltd